* Savara Inc reported a quarterly adjusted loss of 11 cents per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -10 cents. The mean expectation of six analysts for the quarter was for a loss of 11 cents per share. Wall Street expected results to range from -12 cents to -10 cents per share.
* Reported revenue was zero; analysts expected zero.
* Savara Inc's reported EPS for the quarter was a loss of 11 cents.
* The company reported a quarterly loss of $24.25 million.
* Savara Inc shares had fallen by 4.0% this quarter and lost 13.4% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Savara Inc is $10.00 This summary was machine generated from LSEG data November 12 at 03:26 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jan. 1 0001 -0.11 -0.11 Met
Jun. 30 2024 -0.10 -0.12 Missed
Mar. 31 2024 -0.10 -0.11 Missed
Dec. 31 2023 -0.09
Comments